Imunon Inc

NASDAQ:IMNNUnited States

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.

Contact Information

Headquarters

997 Lenox Dr Ste 100LAWRENCEVILLE, NJ, United States 08648

Phone

609-896-9100

Fax

609-896-2200

Executives

Executive Chairman of the Board

Michael Tardugno

President, Chief Executive Officer, Director

Stacy Lindborg

Chief Financial Officer

David Gaiero

Executive Vice President, Chief Scientific Officer

Khursheed Anwer

Executive Vice President, Chief Medical Officer

Sebastien Hazard